A Phase 3 interventional study of ACT-293987 in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 157 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 2nd largest by enrollment, is the only one that started in 2010, is one of 6 in phase 3, and was the 2nd registered.
699 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 709 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 67 across the 12 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 4th largest by enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2010, is one of 31 in phase 3, and was the 24th registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
1 of the studies testing selexipag in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ACT-293987, twice daily
Drug: ACT-293987
Tablets, twice daily
Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.
Time frame: Up to 3 days after study drug discontinuation (Up to 10.5 years)
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention Discontinuation
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Those SAEs occurring during study drug administration, that is, between study drug initiation and three days after study drug discontinuation, are defined as treatment-emergent SAEs.
Time frame: Up to 3 days after study drug discontinuation (Up to 10.5 years)
Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Intervention
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.
Time frame: Up to 10.5 years
Percentage of Alive Participants
Percentage of alive participants were analyzed using Kaplan-Meier (KM) estimates.
Time frame: Baseline (Day 1), Months 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
| Milestone | Selexipag |
|---|---|
| Started | 709 |
| Completed | 424 |
| Not completed | 285 |
| Withdrew: Death | 175 |
| Withdrew: Lost to follow-up | 9 |
| Withdrew: Withdrawal by subject | 31 |
| Withdrew: Other | 70 |
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.
| Participants | Selexipag |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation | 684 |
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Those SAEs occurring during study drug administration, that is, between study drug initiation and three days after study drug discontinuation, are defined as treatment-emergent SAEs.
| Participants | Selexipag |
|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention Discontinuation | 420 |
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug.
| Participants | Selexipag |
|---|---|
| Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Intervention | 129 |
Percentage of alive participants were analyzed using Kaplan-Meier (KM) estimates.
| Percentage of participants | Selexipag |
|---|---|
| KM estimate at Baseline (Day 1) | 100 (100 to 100) |
| KM estimate at Month 3 | 98.4 (97.0 to 99.2) |
| KM estimate at Month 6 | 96.3 (94.4 to 97.6) |
| KM estimate at Month 9 | 94.0 (91.7 to 95.7) |
| KM estimate at Month 12 | 92.0 (89.4 to 94.0) |
| KM estimate at Month 24 | 85.3 (82.0 to 88.0) |
| KM estimate at Month 36 | 79.3 (75.4 to 82.6) |
| KM estimate at Month 48 | 75.2 (70.9 to 78.9) |
| KM estimate at Month 60 | 71.2 (66.5 to 75.3) |
| KM estimate at Month 72 | 66.8 (61.6 to 71.4) |
| KM estimate at Month 84 | 63.3 (57.8 to 68.3) |
| KM estimate at Month 96 | 60.3 (54.4 to 65.7) |
| KM estimate at Month 108 | 56.9 (50.3 to 62.9) |
| KM estimate at Month 120 | 56.9 (50.3 to 62.9) |
Collected over Up to 10.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selexipag | 186/709 (26.2%) | 420/709 (59.2%) | 598/709 (84.3%) |
| Event | Selexipag |
|---|---|
| Pulmonary Arterial HypertensionRespiratory, thoracic and mediastinal disorders | 169/709 |
| Right Ventricular FailureCardiac disorders | 93/709 |
| PneumoniaInfections and infestations | 50/709 |
| SyncopeNervous system disorders | 18/709 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 18/709 |
| Atrial FibrillationCardiac disorders | 17/709 |
| Sudden DeathGeneral disorders | 14/709 |
| Cardiac ArrestCardiac disorders | 13/709 |
| DiarrhoeaGastrointestinal disorders | 12/709 |
| Acute Right Ventricular FailureCardiac disorders | 11/709 |
| Event | Selexipag |
|---|---|
| HeadacheNervous system disorders | 328/709 |
| DiarrhoeaGastrointestinal disorders | 209/709 |
| NauseaGastrointestinal disorders | 135/709 |
| Pain in JawMusculoskeletal and connective tissue disorders | 130/709 |
| Oedema PeripheralGeneral disorders | 90/709 |
| NasopharyngitisInfections and infestations | 88/709 |
| Upper Respiratory Tract InfectionInfections and infestations | 84/709 |
| CoughRespiratory, thoracic and mediastinal disorders | 80/709 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 78/709 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 76/709 |
| Age, Continuous(years) | Selexipag |
|---|---|
| Mean | 47.9 ± 15.19 |
| Sex: Female, Male(Participants) | Selexipag |
|---|---|
| Female | 590 |
| Male | 119 |
| Race/Ethnicity, Customized(Participants) | Selexipag |
|---|---|
| ASIAN | 171 |
| BLACK OR AFRICAN AMERICAN | 15 |
| HISPANIC | 87 |
| OTHER | 8 |
| WHITE | 428 |
| Region of Enrollment(Participants) | Selexipag |
|---|---|
| ARGENTINA | 20 |
| AUSTRALIA | 37 |
| AUSTRIA | 3 |
| BELARUS | 34 |
| BELGIUM | 17 |
| CANADA | 13 |
| CHILE | 31 |
| CHINA | 113 |
| COLOMBIA | 3 |
| CZECH REPUBLIC | 11 |
| DENMARK | 4 |
| FRANCE | 21 |
| GERMANY | 35 |
| GREECE | 6 |
| HUNGARY | 10 |
| INDIA | 15 |
| IRELAND | 4 |
| ISRAEL | 11 |
| ITALY | 4 |
| MALAYSIA | 2 |
| MEXICO | 20 |
| NETHERLANDS | 4 |
| PERU | 6 |
| POLAND | 7 |
| ROMANIA | 9 |
| RUSSIAN FEDERATION | 72 |
| SERBIA | 10 |
| SINGAPORE | 8 |
| SLOVAKIA | 1 |
| SOUTH KOREA | 11 |
| SPAIN | 8 |
| SWEDEN | 10 |
| SWITZERLAND | 2 |
| TAIWAN | 11 |
| THAILAND | 4 |
| TURKEY | 8 |
| UKRAINE | 35 |
| UNITED KINGDOM | 9 |
| UNITED STATES | 80 |
Showing the first 100 of 157 sites across 38 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2010 to primary completion in Aug 2021, 133 months.
Results were first posted in Sep 2022, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 133 months is above that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selexipag
Pulmonary Arterial Hypertension →